CARA- NAS (USA) Also traded in: Germany, UK
Cara Therapeutics Inc

Not Rated

Top Ranked Predictable Companies

$13.2

0.32(2.48%) Volume: 484,266 4:00PM EDT

Avg Vol (1m): 1,642,403

Warning! GuruFocus has detected 1 Severe Warning Sign with NAS:CARA. Click here to check it out.

Market Cap : 660.69 M	Enterprise Value : 493.99 M	PE Ratio : 40.01	PB Ratio : 2.90

RSS

Manual of Stocks™ Web APP

Manual of Stocks™

Sorry. Only PremiumPlus Member can access this feature.

Free Trial

Switch to:

中文

Fundamental
- 5-Year EBITDA Growth Rate
- Altman Z-Score
- Beneish M-Score
- Book Value per Share
- Cash per Share
- Dividends per Share
- E10
- Earnings per Share (Diluted)
- EBIT per Share
- EBITDA per Share
- Enterprise Value
- EPS without NRI
- FFO per Share
- Financial Strength
- Float Percentage Of Total Shares Outstanding
- Free Cash Flow per Share
- Insider Ownership
- Institutional Ownership
- Market Cap
- Net Cash per Share
- Net Current Asset Value
- Net-Net Working Capital
- Operating Cash Flow per Share
- Owner Earnings per Share (TTM)
- Piotroski F-Score
- Predictability Rank
- Profitability Rank
- Quality Rank
- Revenue per Share
- Scaled Net Operating Assets
- Short Interest
- Short Percentage of Float
- Tangible Book per Share
- Total Debt per Share
- Valuation Rank
- YoY EBITDA Growth
- YoY EPS Growth
- YoY Rev. per Sh. Growth
Valuation Ratio
- Asset Turnover
- Buyback Yield %
- Capex-to-Revenue
- Cash Conversion Cycle
- Cash-to-Debt
- COGS-to-Revenue
- Current Ratio
- Days Inventory
- Days Payable
- Days Sales Outstanding
- Debt-to-Asset
- Debt-to-EBITDA
- Debt-to-Equity
- Debt-to-Revenue
- Earnings Yield %
- Earnings Yield (Joel Greenblatt) %
- Effective Interest Rate on Debt %
- Equity-to-Asset
- EV-to-EBIT
- EV-to-EBITDA
- EV-to-Revenue
- Forward PE Ratio
- Forward Rate of Return (Yacktman) %
- Goodwill-to-Asset
- Gross-Profit-to-Asset %
- Interest Coverage
- Inventory Turnover
- Inventory-to-Revenue
- LT-Debt-to-Total-Asset
- PB Ratio
- PE Ratio
- PE Ratio
- PE Ratio without NRI
- PEG Ratio
- Price-to-Free-Cash-Flow
- Price-to-Funds-From-Operations
- Price-to-Operating-Cash-Flow
- Price-to-Owner-Earnings
- Price-to-Tangible-Book
- PS Ratio
- Quick Ratio
- Return-on-Tangible-Asset
- Return-on-Tangible-Equity
- ROA %
- ROC %
- ROC (Joel Greenblatt) %
- ROCE %
- ROE %
- ROE % Adjusted to Book Value
- ROIC %
- Shares Buyback Ratio %
- Shiller PE Ratio
- Short Ratio
- Sloan Ratio %
- Total Payout Ratio
- Total Payout Yield %
- WACC %
Profitability
- FCF Margin %
- Gross Margin %
- Net Interest Margin (Bank Only) %
- Net Margin %
- Operating Margin %
Price
- Beta
- Earnings Power Value (EPV)
- GF Value
- Graham Number
- Intrinsic Value: DCF (Earnings Based)
- Intrinsic Value: DCF (FCF Based)
- Intrinsic Value: Projected FCF
- Margin of Safety % (DCF Earnings Based)
- Median PS Value
- Peter Lynch Fair Value
Dividends
- 3-Year Dividend Growth Rate
- 5-Year Dividend Growth Rate
- 5-Year Yield-on-Cost %
- Dividend Payout Ratio
- Dividend Yield %
- Dividend-Payout-to-FFO
- Forward Dividend Yield %
Income Statement
- Cost of Goods Sold
- Credit Losses Provision
- Depreciation, Depletion and Amortization
- EBIT
- EBITDA
- EPS (Basic)
- EPS (Diluted)
- Fees and Other Income
- Gross Profit
- Interest Expense
- Interest Expense (Positive)
- Interest Income
- Net Income
- Net Income (Continuing Operations)
- Net Income (Discontinued Operations)
- Net Interest Income
- Net Interest Income (for Banks)
- Net Investment Income
- Net Policyholder Benefits/Claims
- Non Interest Income
- Non Operating Income
- Operating Income
- Other Expense
- Other Income (Expense)
- Other Income (Minority Interest)
- Other Noninterest Expense
- Other Operating Expense
- Policy Acquisition Expense
- Pre-Tax Income
- Preferred Dividends
- Research & Development
- Revenue
- Selling, General, & Admin. Expense
- Shares Outstanding (Basic Average)
- Shares Outstanding (Diluted Average)
- SpecialCharges
- Tax Expense
- Tax Provision
- Tax Rate %
- Total Expenses
- Total Noninterest Expense
- Total Operating Expense
- Total Premiums Earned
Balance Sheet
- Accounts Payable
- Accounts Payable & Accrued Expense
- Accounts Payable & Accrued Expense for Financial Companies
- Accounts Receivable
- Accumulated Depreciation
- Accumulated other comprehensive income (loss)
- Additional Paid-In Capital
- Allowance For Loans And Lease Losses
- Buildings And Improvements
- Cash And Cash Equivalents
- Cash and cash equivalents
- Cash, Cash Equivalents, Marketable Securities
- Common Stock
- Construction In Progress
- Current Accrued Expense
- Current Deferred Revenue
- Current Deferred Taxes Liabilities
- Deferred Policy Acquisition Costs
- DeferredTaxAndRevenue
- Equity Investments
- Fixed Maturity Investment
- Future Policy Benefits
- Goodwill
- Gross Loan
- Gross Property, Plant and Equipment
- Intangible Assets
- Inventories, Finished Goods
- Inventories, Inventories Adjustments
- Inventories, Other
- Inventories, Raw Materials & Components
- Inventories, Work In Process
- Investments And Advances
- Land And Improvements
- Loans Receivable
- Long-Term Capital Lease Obligation
- Long-Term Debt
- Long-Term Debt & Capital Lease Obligation
- Machinery, Furniture, Equipment
- Marketable Securities
- Minority Interest
- Money Market Investments
- Net Loan
- NonCurrent Deferred Liabilities
- Notes Receivable
- Other Assets for Banks
- Other Assets for Insurance Companies
- Other Current Assets
- Other Current Liabilities
- Other Current Payables
- Other Current Receivables
- Other Gross PPE
- Other Liabilities for Banks
- Other Liabilities for Insurance Companies
- Other Long Term Assets
- Other Long-Term Liabilities
- Other Stockholders Equity
- PensionAndRetirementBenefit
- Policyholder Funds
- Preferred Stock
- Property, Plant and Equipment
- Retained Earnings
- Securities & Investments
- Shares Outstanding (EOP)
- Short-Term Capital Lease Obligation
- Short-Term Debt
- Short-Term Debt & Capital Lease Obligation
- Short-term investments
- Total Assets
- Total Current Assets
- Total Current Liabilities
- Total Deposits
- Total Equity
- Total Inventories
- Total Liabilities
- Total Long-Term Assets
- Total Long-Term Liabilities
- Total Receivables
- Total Stockholders Equity
- Total Tax Payable
- Treasury Stock
- Unearned Income
- Unearned Premiums
- Unpaid Loss & Loss Reserve
Cashflow Statement
- All Taxes Paid
- Asset Impairment Charge
- Capital Expenditure
- Cash Flow for Dividends
- Cash Flow from Discontinued Operations
- Cash Flow from Financing
- Cash Flow from Investing
- Cash Flow from Operations
- Cash Flow from Others
- Cash From Discontinued Investing Activities
- Cash from Discontinued Operating Activities
- Cash From Other Investing Activities
- Cash Paid for Insurance Activities
- Cash Payments
- Cash Payments for Deposits by Banks and Customers
- Cash Payments for Loans
- Cash Receipts from Deposits by Banks and Customers
- Cash Receipts from Fees and Commissions
- Cash Receipts from Loans
- Cash Receipts from Operating Activities
- Cash Receipts from Securities Related Activities
- Cash Receipts from Tax Refunds
- Cash Received from Insurance Activities
- Change In Inventory
- Change In Other Working Capital
- Change In Payables And Accrued Expense
- Change In Prepaid Assets
- Change In Receivables
- Change In Working Capital
- Deferred Tax
- Depreciation, Depletion and Amortization
- Dividends Paid
- Dividends Received
- Effect of Exchange Rate Changes
- FFO
- Free Cash Flow
- Interest and Commission Paid
- Interest Paid
- Interest Received
- Issuance of Debt
- Issuance of Stock
- Net Change in Cash
- Net Income From Continuing Operations
- Net Intangibles Purchase And Sale
- Net Issuance of Debt
- Net Issuance of Preferred Stock
- Other Cash Payments from Operating Activities
- Other Cash Receipts from Operating Activities
- Other Financing
- Payments of Debt
- Payments on Behalf of Employees
- Payments to Suppliers for Goods and Services
- Purchase Of Business
- Purchase Of Investment
- Purchase Of Property, Plant, Equipment
- Receipts from Customers
- Receipts from Government Grants
- Repurchase of Stock
- Sale Of Business
- Sale Of Investment
- Sale Of Property, Plant, Equipment
- Stock Based Compensation
- Taxes Refund Paid

Cara Therapeutics Enterprise Value

: $494.0 Mil (As of Today)

View and export this data going back to 2014. Start your Free Trial

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cara Therapeutics's Enterprise Value is $494.0 Mil. Cara Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 was $11.8 Mil. Therefore, Cara Therapeutics's EV-to-EBIT ratio for today is 41.78.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Cara Therapeutics's Enterprise Value is $494.0 Mil. Cara Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2021 was $12.0 Mil. Therefore, Cara Therapeutics's EV-to-EBITDA ratio for today is 41.00.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Cara Therapeutics's Enterprise Value is $494.0 Mil. Cara Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2021 was $128.9 Mil. Therefore, Cara Therapeutics's EV-to-Revenue ratio for today is 3.83.

Cara Therapeutics Enterprise Value Historical Data

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics Annual Data
	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20
Enterprise Value						195.31	307.22	352.74	601.98	578.92

Cara Therapeutics Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Enterprise Value																501.16	675.16	479.56	578.92	919.42

Competitive Comparison

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.

Cara Therapeutics Enterprise Value Distribution

* The bar in red indicates where Cara Therapeutics's Enterprise Value falls into.

Cara Therapeutics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Cara Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2020 is calculated as

	Enterprise Value (A: Dec. 2020 )
=	Market Cap	+	Preferred Stock	+	Long-Term Debt & Capital Lease Obligation
=	754.566386	+	0	+	3.673
+	Short-Term Debt & Capital Lease Obligation	+	Minority Interest	-	Cash, Cash Equivalents, Marketable Securities
+	1.602	+	0	-	180.925
=	578.9

Cara Therapeutics's Enterprise Value for the quarter that ended in Mar. 2021 is calculated as

	Enterprise Value (Q: Mar. 2021 )
=	Market Cap	+	Preferred Stock	+	Long-Term Debt & Capital Lease Obligation
=	1086.112222	+	0	+	3.25
+	Short-Term Debt & Capital Lease Obligation	+	Minority Interest	-	Cash, Cash Equivalents, Marketable Securities
+	1.639	+	0	-	171.582
=	919.4

Cara Therapeutics (NAS:CARA) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Cara Therapeutics's EV-to-EBIT for today is

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	493.993	/	11.825
	=	41.78

Cara Therapeutics's current Enterprise Value is $494.0 Mil.
Cara Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 was -25.884 (Jun. 2020 ) + -17.02 (Sep. 2020 ) + 78.29 (Dec. 2020 ) + -23.561 (Mar. 2021 ) = $11.8 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Cara Therapeutics's EV-to-EBITDA for today is:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA(TTM)
	=	493.993	/	12.049
	=	41.00

Cara Therapeutics's current Enterprise Value is $494.0 Mil.
Cara Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2021 was -25.836 (Jun. 2020 ) + -16.969 (Sep. 2020 ) + 78.352 (Dec. 2020 ) + -23.498 (Mar. 2021 ) = $12.0 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Cara Therapeutics's EV-to-Revenue for today is:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	493.993	/	128.924
	=	3.83

Cara Therapeutics's current Enterprise Value is $494.0 Mil.
Cara Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2021 was 5.634 (Jun. 2020 ) + 9.266 (Sep. 2020 ) + 112.089 (Dec. 2020 ) + 1.935 (Mar. 2021 ) = $128.9 Mil.

Cara Therapeutics Enterprise Value Related Terms

Cara Therapeutics Enterprise Value Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Mobile App Email Alerts Referral Program Affiliate Program FAQ Contact Us 中文
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

GuruFocus Screeners

My Screeners

Value Screens

Model Portfolios

Tools

Market Valuation

Economic Indicators

By Country

Articles

Submit Articles

Cara Therapeutics Enterprise Value

Cara Therapeutics Enterprise Value Historical Data

Cara Therapeutics Enterprise Value Calculation

Cara Therapeutics Enterprise Value Related Terms

Cara Therapeutics Enterprise Value Headlines